Cornerstone Therapeutics Inc. Completes Acquisition of EKR Therapeutics, Inc.
6/27/2012 9:04:40 AM
More...
|
Cornerstone Therapeutics Inc. Reports First Quarter 2012 Financial Results
5/15/2012 9:03:52 AM
More...
|
Cornerstone Therapeutics Inc. to Acquire EKR Therapeutics, Inc. for $125 Million Cash, Plus $25 Million in Milestones
5/15/2012 6:47:57 AM
More...
|
EKR Therapeutics, Inc. Names Two Independent Directors and Reaffirms Board of Directors to Lead Company Growth in the Critical Care Sector
12/15/2011 9:45:16 AM
More...
|
EKR Therapeutics, Inc. Announces Robert P. Roche Jr. Joins Board of Directors
10/24/2011 10:07:47 AM
More...
|
EKR Therapeutics, Inc. Announces Senior Management Change
10/14/2011 9:28:36 AM
More...
|
Rolf A. Classon Joins Board of EKR Therapeutics, Inc.
5/13/2011 10:16:21 AM
More...
|
EKR Therapeutics, Inc. Release: New Study Demonstrates Ready-to Use Cardene(R) I.V. More Effective than Labetalol for Immediate Control of Blood Pressure in Emergency Room Patients
9/29/2010 8:08:10 AM
More...
|
EKR Therapeutics, Inc. Names John E. Bailye New Chief Executive Officer
7/22/2010 10:31:39 AM
More...
|
EKR Therapeutics, Inc. Appoints John Bailye as Interim President & Chief Executive Officer
3/4/2010 6:57:06 AM
More...
|
|